Immune Pharmaceuticals Inc. (Nasdaq: IMNP) named Dr. Daniel Teper to lead the oncology business of its Cytovia subsidiary and to pursue a potential spin-off of Cytovia. The stock price dropped 74 cents to close at $2.79.